Miriam Merad, M.D.; Ph.D. is a Professor of Oncological Science, Medicine (Hem/Onc division) and Immunology and a Member of the Immunology Institute and The Tisch Cancer Institute at the Mount Sinai School of Medicine in New York. Dr. Merad obtained her M.D. at the University of Algiers, Algeria. She did her residency in Hematology and Oncology in Paris, France and obtained her Ph.D. in immunology in collaboration between Stanford University and University of Paris VII. She was recruited to Mount Sinai School of Medicine in 2004 and was promoted to the rank of Associate Professor with Tenure in 2007 and to Full Professor in 2010. Dr. Merad obtained an endowed Professorship in 2014. In 2010 Dr. Merad became the program leader of the Cancer Immunology Immunotherapy group at The Tisch Cancer Institute and the director of the Human Immunomonitoring Center. Dr. Merad also serves as the Associate Director for the M.D. Ph.D. program at Mount Sinai Medical School. Dr. Merad's laboratory studies the mechanisms that regulate the development and function of the mononuclear phagocyte lineage including dendritic cells and macrophages. Her laboratory has extensively studied the mechanisms that control dendritic cells and macrophage homeostasis in different tissues. Dr. Merad has also made seminal discoveries in macrophage biology revealing their embryonic origin and their local maintenance in situ. Dr. Merad belongs to the Immgen Consortia to help decipher the transcriptional regulation of the tissue dendritic cell and macrophage lineage. Currently, one of the major goals of her laboratory is to identify the contribution of phagocytes to disease outcome including cancer and microbial immunity. Dr. Merad has authored more than 150 primary papers and reviews in high profile journals and has obtained extensive NIH funding for her studies on dendritic cells and macrophage biology in mice and humans.